An integrated in vitro model for simultaneous assessment of drug uptake, metabolism, and efflux

Molecular Pharmaceutics

Volumn 10, Issue 8, 2013, Pages 3152-3163

  Neve, Etienne P A ^a   Artursson, Per ^b   Ingelman Sundberg, Magnus ^a   Karlgren, Maria ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

adenovirus infection; cellular models; CYP3A4; drug metabolism; drug transport; MDR1; OATP1B1; triple transfection

Indexed keywords

ATORVASTATIN; COMPLEMENTARY DNA; CYTOCHROME B5; CYTOCHROME P450 3A4; CYTOCHROME P450 REDUCTASE; ESTRADIOL 17 GLUCURONIDE; ESTRONE SULFATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MIDAZOLAM; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B1; SIMVASTATIN; UNCLASSIFIED DRUG; WARFARIN;

ACTIVE TRANSPORT; ADENOVIRUS INFECTION; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG TRANSPORT; DRUG UPTAKE; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MODEL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; WESTERN BLOTTING;

ADENOVIRIDAE; BIOLOGICAL TRANSPORT; CELL LINE; CYTOCHROME P-450 CYP3A; CYTOCHROMES B5; HUMANS; NADPH-FERRIHEMOPROTEIN REDUCTASE; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; SIMVASTATIN;

EID: 84881334936     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp400202d     Document Type: Article

References (57)

1. Wienkers, L. C.; Heath, T. G. Predicting in vivo drug interactions from in vitro drug discovery data Nat. Rev. Drug Discovery 2005, 4, 825-33
2. Keogh, J. P. Membrane transporters in drug development Adv. Pharmacol. 2012, 63, 1-42
3. Giacomini, K. M.; Huang, S. M.; Tweedie, D. J.; Benet, L. Z.; Brouwer, K. L.; Chu, X.; Dahlin, A.; Evers, R.; Fischer, V.; Hillgren, K. M.; Hoffmaster, K. A.; Ishikawa, T.; Keppler, D.; Kim, R. B.; Lee, C. A.; Niemi, M.; Polli, J. W.; Sugiyama, Y.; Swaan, P. W.; Ware, J. A.; Wright, S. H.; Yee, S. W.; Zamek-Gliszczynski, M. J.; Zhang, L. Membrane transporters in drug development Nat. Rev. Drug Discovery 2010, 9, 215-36
4. Hagenbuch, B.; Meier, P. J. Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties Pflugers Arch. 2004, 447, 653-65
5. Smith, N. F.; Figg, W. D.; Sparreboom, A. Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination Expert Opin. Drug Metab. Toxicol. 2005, 1, 429-45
6. Nakanishi, T.; Tamai, I. Genetic polymorphisms of OATP transporters and their impact on intestinal absorption and hepatic disposition of drugs Drug Metab. Pharmacokinet. 2012, 27, 106-21
7. Niemi, M.; Pasanen, M. K.; Neuvonen, P. J. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake Pharmacol. Rev. 2011, 63, 157-81
8. Bech-Hansen, N. T.; Till, J. E.; Ling, V. Pleiotropic phenotype of colchicine-resistant CHO cells: cross-resistance and collateral sensitivity J. Cell Physiol. 1976, 88, 23-31
9. Borst, P.; Schinkel, A. H.; Smit, J. J.; Wagenaar, E.; Van Deemter, L.; Smith, A. J.; Eijdems, E. W.; Baas, F.; Zaman, G. J. Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals Pharmacol. Ther. 1993, 60, 289-99
10. Gottesman, M. M.; Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter Annu. Rev. Biochem. 1993, 62, 385-427
11. Hofsli, E.; Nissen-Meyer, J. Reversal of drug resistance by erythromycin: erythromycin increases the accumulation of actinomycin D and doxorubicin in multidrug-resistant cells Int. J. Cancer 1989, 44, 149-54
12. Kwatra, D.; Vadlapatla, R. K.; Vadlapudi, A. D.; Pal, D.; Mitra, A. K. Interaction of gatifloxacin with efflux transporters: a possible mechanism for drug resistance Int. J. Pharmaceutics 2010, 395, 114-21
13. Mechetner, E. B.; Roninson, I. B. Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 5824-8
14. Roninson, I. B.; Abelson, H. T.; Housman, D. E.; Howell, N.; Varshavsky, A. Amplification of specific DNA sequences correlates with multi-drug resistance in Chinese hamster cells Nature 1984, 309, 626-8
15. Ueda, K.; Okamura, N.; Hirai, M.; Tanigawara, Y.; Saeki, T.; Kioka, N.; Komano, T.; Hori, R. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone J. Biol. Chem. 1992, 267, 24248-52
16. Zhou, S. F. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition Xenobiotica 2008, 38, 802-32
17. Englund, G.; Hallberg, P.; Artursson, P.; Michaelsson, K.; Melhus, H. Association between the number of coadministered P-glycoprotein inhibitors and serum digoxin levels in patients on therapeutic drug monitoring BMC Med. 2004, 2, 8
18. Guengerich, F. P. Cytochrome P-450 3A4: regulation and role in drug metabolism Annu. Rev. Pharmacol. Toxicol. 1999, 39, 1-17
19. Ingelman-Sundberg, M.; Sim, S. C.; Gomez, A.; Rodriguez-Antona, C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects Pharmacol. Ther. 2007, 116, 496-526
20. Lin, J. H. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein Adv. Drug Delivery Rev. 2003, 55, 53-81
21. Pal, D.; Mitra, A. K. MDR- and CYP3A4-mediated drug-drug interactions J. Neuroimmun. Pharmacol. 2006, 1, 323-39
22. van Waterschoot, R. A.; Lagas, J. S.; Wagenaar, E.; van der Kruijssen, C. M.; van Herwaarden, A. E.; Song, J. Y.; Rooswinkel, R. W.; van Tellingen, O.; Rosing, H.; Beijnen, J. H.; Schinkel, A. H. Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity Cancer Res. 2009, 69, 8996-9002
23. van Waterschoot, R. A.; Schinkel, A. H. A critical analysis of the interplay between cytochrome P450 3A and P-glycoprotein: recent insights from knockout and transgenic mice Pharmacol. Rev. 2011, 63, 390-410
24. Benet, L. Z. The drug transporter-metabolism alliance: uncovering and defining the interplay Mol. Pharmaceutics 2009, 6, 1631-43
25. Karlgren, M.; Vildhede, A.; Norinder, U.; Wisniewski, J. R.; Kimoto, E.; Lai, Y.; Haglund, U.; Artursson, P. Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions J. Med. Chem. 2012, 55, 4740-63
26. Li, J.; Culman, J.; Hortnagl, H.; Zhao, Y.; Gerova, N.; Timm, M.; Blume, A.; Zimmermann, M.; Seidel, K.; Dirnagl, U.; Unger, T. Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury FASEB J. 2005, 19, 617-9
27. Ohtsuki, S.; Uchida, Y.; Kubo, Y.; Terasaki, T. Quantitative targeted absolute proteomics-based ADME research as a new path to drug discovery and development: methodology, advantages, strategy, and prospects J. Pharm. Sci. 2011, 100, 3547-59
28. Shitara, Y.; Sugiyama, Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions Pharmacol. Ther. 2006, 112, 71-105
29. Lennernas, H. Clinical pharmacokinetics of atorvastatin Clin. Pharmacokinet. 2003, 42, 1141-60
30. Hochman, J. H.; Pudvah, N.; Qiu, J.; Yamazaki, M.; Tang, C.; Lin, J. H.; Prueksaritanont, T. Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin Pharm. Res. 2004, 21, 1686-91
31. Link, E.; Parish, S.; Armitage, J.; Bowman, L.; Heath, S.; Matsuda, F.; Gut, I.; Lathrop, M.; Collins, R. SLCO1B1 variants and statin-induced myopathy - a genomewide study N. Engl. J. Med. 2008, 359, 789-99
32. Neuvonen, P. J.; Niemi, M.; Backman, J. T. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance Clin. Pharmacol. Ther. 2006, 80, 565-81
33. Niemi, M. Transporter pharmacogenetics and statin toxicity Clin. Pharmacol. Ther. 2010, 87, 130-3
34. Crespi, C. L.; Fox, L.; Stocker, P.; Hu, M.; Steimel, D. T. Analysis of drug transport and metabolism in cell monolayer systems that have been modified by cytochrome P4503A4 cDNA-expression Eur. J. Pharm. Sci. 2000, 12, 63-8
35. Fahrmayr, C.; Konig, J.; Auge, D.; Mieth, M.; Fromm, M. F. Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells Br. J. Pharmacol. 2012, 165, 1836-47
36. Tang, F.; Horie, K.; Borchardt, R. T. Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm. Res. 2002, 19, 765-72
37. Kwatra, D.; Budda, B.; Vadlapudi, A. D.; Vadlapatla, R. K.; Pal, D.; Mitra, A. K. Transfected MDCK Cell Line with Enhanced Expression of CYP3A4 and P-Glycoprotein as a Model To Study Their Role in Drug Transport and Metabolism Mol. Pharmaceutics 2012, 9, 1877-1866
38. Ahlin, G.; Hilgendorf, C.; Karlsson, J.; Szigyarto, C. A.; Uhlen, M.; Artursson, P. Endogenous gene and protein expression of drug-transporting proteins in cell lines routinely used in drug discovery programs Drug Metab. Dispos. 2009, 37, 2275-83
39. Karlgren, M.; Ahlin, G.; Bergstrom, C. A.; Svensson, R.; Palm, J.; Artursson, P. In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions Pharm. Res. 2012, 29, 411-26
40. Konig, J.; Cui, Y.; Nies, A. T.; Keppler, D. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane Am J Physiol Gastrointest Liver Physiol 2000, 278, G156-64
41. Wang, Y.; Liao, M.; Hoe, N.; Acharya, P.; Deng, C.; Krutchinsky, A. N.; Correia, M. A. A role for protein phosphorylation in cytochrome P450 3A4 ubiquitin-dependent proteasomal degradation J. Biol. Chem. 2009, 284, 5671-84
42. Gillen, C. M.; Forbush, B., 3rd Functional interaction of the K-Cl cotransporter (KCC1) with the Na-K-Cl cotransporter in HEK-293 cells Am. J. Physiol. 1999, 276 (2 Pt 1) C328-36
43. Watanabe, T.; Kusuhara, H.; Maeda, K.; Kanamaru, H.; Saito, Y.; Hu, Z.; Sugiyama, Y. Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans Drug Metab. Dispos. 2010, 38, 215-22
44. Lins, R. L.; Matthys, K. E.; Verpooten, G. A.; Peeters, P. C.; Dratwa, M.; Stolear, J. C.; Lameire, N. H. Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients Nephrol. Dial. Transplant 2003, 18, 967-76
45. Schachter, M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update Fundam. Clin. Pharmacol. 2005, 19, 117-25
46. Chen, C.; Mireles, R. J.; Campbell, S. D.; Lin, J.; Mills, J. B.; Xu, J. J.; Smolarek, T. A. Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1 Drug Metab. Dispos. 2005, 33, 537-46
47. Jacobsen, W.; Kuhn, B.; Soldner, A.; Kirchner, G.; Sewing, K. F.; Kollman, P. A.; Benet, L. Z.; Christians, U. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin Drug Metab. Dispos. 2000, 28, 1369-78
48. Amundsen, R.; Christensen, H.; Zabihyan, B.; Asberg, A. Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin Drug Metab. Dispos. 2010, 38, 1499-504
49. Wu, X.; Whitfield, L. R.; Stewart, B. H. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter Pharm. Res. 2000, 17, 209-15
50. Fahrmayr, C.; Konig, J.; Auge, D.; Mieth, M.; Munch, K.; Segrestaa, J.; Pfeifer, T.; Treiber, A.; Fromm, M. Phase I and II metabolism and MRP2-mediated export of bosentan in a MDCKII-OATP1B1-CYP3A4-UGT1A1-MRP2 quadruple-transfected cell line Br. J. Pharmacol. 2013, 169, 21-33
51. Di, L.; Whitney-Pickett, C.; Umland, J. P.; Zhang, H.; Zhang, X.; Gebhard, D. F.; Lai, Y.; Federico, J. J., 3rd; Davidson, R. E.; Smith, R.; Reyner, E. L.; Lee, C.; Feng, B.; Rotter, C.; Varma, M. V.; Kempshall, S.; Fenner, K.; El-Kattan, A. F.; Liston, T. E.; Troutman, M. D. Development of a new permeability assay using low-efflux MDCKII cells J. Pharm. Sci. 2011, 100, 4974-85
52. Liao, M.; Raczynski, A. R.; Chen, M.; Chuang, B. C.; Zhu, Q.; Shipman, R.; Morrison, J.; Lee, D.; Lee, F. W.; Balani, S. K.; Xia, C. Q. Inhibition of hepatic organic anion-transporting polypeptide by RNA interference in sandwich-cultured human hepatocytes: an in vitro model to assess transporter-mediated drug-drug interactions Drug Metab. Dispos. 2010, 38, 1612-22
53. Williamson, B.; Soars, A. C.; Owen, A.; White, P.; Riley, R. J.; Soars, M. G. Dissecting the relative contribution of OATP1B1-mediated uptake of xenobiotics into human hepatocytes using siRNA Xenobiotica 2013, 10.3109/00498254.2013.776194
54. Yue, W.; Abe, K.; Brouwer, K. L. Knocking down breast cancer resistance protein (Bcrp) by adenoviral vector-mediated RNA interference (RNAi) in sandwich-cultured rat hepatocytes: a novel tool to assess the contribution of Bcrp to drug biliary excretion Mol. Pharmaceutics 2009, 6, 134-43
55. Noe, J.; Portmann, R.; Brun, M. E.; Funk, C. Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3 Drug Metab. Dispos. 2007, 35, 1308-14
56. Kameyama, Y.; Yamashita, K.; Kobayashi, K.; Hosokawa, M.; Chiba, K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells Pharmacogenet. Genomics 2005, 15, 513-22
57. Pasanen, M. K.; Neuvonen, M.; Neuvonen, P. J.; Niemi, M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid Pharmacogenet. Genomics 2006, 16, 873-9